Cardinal Health Smashes 52-Week High After Strong Quarter

Impact · against what's priced in

Cardinal Health is a strong buy on the back of a significant beat and raise. The upward revision of FY2026 EPS guidance to $10.15–$10.35, combined with triple-digit profit growth in the Global Medical Products segment, provides a concrete catalyst for further price appreciation.

CAH+0.70

No priced-in read yet

In context

The company beat consensus on both EPS ($2.63 vs $2.35) and sales ($65.63B vs $64.14B) while raising its FY2026 EPS guidance to $10.15–$10.35 from 'at least $10'.

Read from the article alone

• earnings▲2%
• healthcare
• guidance
• pharmaceuticals
• CAH
• medical distribution
• profit growth
• tariffs

Top 1 mover · tap to explore